PMID- 26878658
OWN - NLM
STAT- MEDLINE
DCOM- 20171212
LR  - 20221110
IS  - 1476-5365 (Electronic)
IS  - 0268-3369 (Print)
IS  - 0268-3369 (Linking)
VI  - 51
IP  - 5
DP  - 2016 May
TI  - Invariant natural killer T cells in hematopoietic stem cell transplantation: 
      killer choice for natural suppression.
PG  - 629-37
LID - 10.1038/bmt.2015.335 [doi]
AB  - Invariant natural killer T cells (iNKTs) are innate-like lipid-reactive T 
      lymphocytes that express an invariant T-cell receptor (TCR). Following engagement 
      of the iTCR, iNKTs rapidly secrete copious amounts of Th1 and Th2 cytokines and 
      promote the functions of several immune cells including NK, T, B and dendritic 
      cells. Accordingly, iNKTs bridge the innate and adaptive immune responses and 
      modulate susceptibility to autoimmunity, infection, allergy and cancer. 
      Allogeneic hematopoietic stem cell transplantation (HSCT) is one of the most 
      effective treatments for patients with hematologic malignancies. However, the 
      beneficial graft versus leukemia (GvL) effect mediated by the conventional T 
      cells contained within the allograft is often hampered by the concurrent 
      occurrence of graft versus host disease (GvHD). Thus, developing strategies that 
      can dissociate GvHD from GvL remain clinically challenging. Several preclinical 
      and clinical studies demonstrate that iNKTs significantly attenuate GvHD without 
      abrogating the GvL effect. Besides preserving the GvL activity of the donor 
      graft, iNKTs themselves exert antitumor immune responses via direct and indirect 
      mechanisms. Herein, we review the various mechanisms by which iNKTs provide 
      antitumor immunity and discuss their roles in GvHD suppression. We also highlight 
      the opportunities and obstacles in manipulating iNKTs for use in the cellular 
      therapy of hematologic malignancies.
FAU - Guan, P
AU  - Guan P
AD  - Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, 
      USA.
FAU - Bassiri, H
AU  - Bassiri H
AUID- ORCID: 0000-0001-6532-8478
AD  - Division of Infectious Diseases, The Children's Hospital of Philadelphia, 
      Philadelphia, PA, USA.
FAU - Patel, N P
AU  - Patel NP
AD  - Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, 
      USA.
FAU - Nichols, K E
AU  - Nichols KE
AD  - Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
FAU - Das, R
AU  - Das R
AD  - Department of Physiology, Michigan State University, East Lansing, MI, USA.
LA  - eng
GR  - K08 CA166184/CA/NCI NIH HHS/United States
GR  - K22 CA188149/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20160215
PL  - England
TA  - Bone Marrow Transplant
JT  - Bone marrow transplantation
JID - 8702459
SB  - IM
MH  - Graft vs Host Disease
MH  - Graft vs Leukemia Effect
MH  - Hematologic Neoplasms/*therapy
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - Natural Killer T-Cells/*immunology
MH  - *Transplantation Immunology
PMC - PMC9644293
MID - NIHMS1839496
COIS- CONFLICT OF INTEREST The authors declare no conflict of interest.
EDAT- 2016/02/16 06:00
MHDA- 2017/12/13 06:00
PMCR- 2022/11/09
CRDT- 2016/02/16 06:00
PHST- 2015/07/11 00:00 [received]
PHST- 2015/11/24 00:00 [revised]
PHST- 2015/11/27 00:00 [accepted]
PHST- 2016/02/16 06:00 [entrez]
PHST- 2016/02/16 06:00 [pubmed]
PHST- 2017/12/13 06:00 [medline]
PHST- 2022/11/09 00:00 [pmc-release]
AID - bmt2015335 [pii]
AID - 10.1038/bmt.2015.335 [doi]
PST - ppublish
SO  - Bone Marrow Transplant. 2016 May;51(5):629-37. doi: 10.1038/bmt.2015.335. Epub 
      2016 Feb 15.